
Nuvalent (NUVL) Stock Forecast & Price Target
Nuvalent (NUVL) Analyst Ratings
Bulls say
Nuvalent is in a strong position with two promising drug candidates in its pipeline, NVL-520 and NVL-330, which target two different types of lung cancer with high market potential. This, combined with Oric’s focus on HER2+ NSCLC, makes for a complementary partnership and sets Nuvalent up for potential growth in the future of the cancer treatment market. Additionally, the positive clinical trial results for zidesamtinib and the low levels of adverse events bode well for its potential success and profitability.
Bears say
Nuvalent is currently a clinical-stage company with no approved products. Despite its promising pipeline targeting cancer-related kinases, the company has yet to see any revenue. Additionally, with larger competitors dominating the market, Nuvalent's projected peak revenues may be optimistic. The company also faces potential challenges to their market exclusivity, which could weaken their competitive position.
This aggregate rating is based on analysts' research of Nuvalent and is not a guaranteed prediction by Public.com or investment advice.
Nuvalent (NUVL) Analyst Forecast & Price Prediction
Start investing in Nuvalent (NUVL)
Order type
Buy in
Order amount
Est. shares
0 shares